Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD3+CD8+ Cytotoxic T Lymphocyte (CTL)
- Target
- CTL
- Molecular classification
- T cell, Immune cell, Lymphocyte
01
Overview
CD3+CD8+ cytotoxic T lymphocytes (CTLs) are a subset of T cells characterized by the co-expression of the CD3 and CD8 surface markers. These cells play a central role in the adaptive immune response, primarily responsible for identifying and destroying infected or malignant cells. They recognize antigens presented by MHC I molecules and kill target cells through perforin/granzyme release, FasL-Fas interaction, and cytokine secretion. CTLs are important in cancer immunotherapy, and high densities of tumor-infiltrating CD3+ and CD8+ lymphocytes are associated with improved overall survival in several cancers. Modulation or targeting these populations is an area of active research.
- Other names
- CD3+CD8+ T cellCytotoxic T LymphocyteKiller T cellCD8+ T cell
02
Mechanism of action
Direct killing of target cells through perforin/granzyme release and FasL-Fas interaction; cytokine-mediated modulation of immune responses.
03
Biological functions
CytotoxicityAntigen recognitionImmune responseApoptosis inductionCytokine secretionCell killing
04
Disease associations
CancerViral infectionAutoimmune diseaseImmunodeficiency
05
Safety considerations
Cytokine release syndrome (CRS)Immune-related adverse events (irAEs)On-target/off-tumor toxicityGraft-versus-host disease (GvHD)
06
Interacting drugs
Checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4)
4 more in the full profile.
07
Biomarkers
Tumor-infiltrating lymphocytes (TILs)CD8+ T cell densityPD-1 expressionCTLA-4 expressionIFN-γ productionGranzyme B levels
Beyond the preview
Go deeper on CD3+CD8+ Cytotoxic T Lymphocyte (CTL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3+CD8+ Cytotoxic T Lymphocyte (CTL).